As a result, combining TERT and EGFR inhibition has been proposed as a new combination therapy.12 In this study, we, therefore, examined TERT or GABPB1 silencing, combined with inhibition of EGFR signaling in 2 GBM models, and assessed the value of MRS to detect response. The gene discussed is GABPB1; the disease is glioblastoma.